Latest Period
Q1 2026
Security Snapshot
Grace Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GRCE) Institutional Ownership
CUSIP: 00439U104
13F Institutional Holders and Ownership History from Q3 2024 to Q1 2026
Institutions Reporting
34
Shares (Excl. Options)
4,264,472
Price
$4.63
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- GRCE on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 4,264,472
- Total 13F value
- $19,744,993
- Portfolio coverage rank
- 0%
- Share change
- -56,070
- Value change
- +$1,574,724
- Number of holders
- 34
- Shares outstanding
- 17,347,737
- SEC-reported price per share
- $2.43
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- GRCE - Grace Therapeutics, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 00439U104.
- 34 institutions reported positions in Q1 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 22 to 34 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $14,995,992 to $19,744,993.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 34 institutions filings for Q1 2026.
Security key
00439U104
Latest holder period
Q1 2026
13F holders
34
13D/G owners
3
CIK / CUSIP context first
Open Q1 2026 holders
GRCE full holder history
Grace Therapeutics, Inc. SEC filings
Grace Therapeutics, Inc. company facts
Grace Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 00439U104:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
GRCE
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ADAR1 Capital Management, LLC | 9.9% | 0% | $5,719,029 | +$228,555 | 1,717,426 | +4.2% | ADAR1 Capital Management GP, LLC | 31 Mar 2026 |
| Nantahala Capital Management, LLC | 10% | 0% | $5,616,773 | +$646,500 | 1,586,659 | +13% | Nantahala Capital Management, LLC | 31 Dec 2025 |
| HIRSCHMAN ORIN | 5.9% | -40% | $3,157,115 | -$1,444,764 | 907,217 | -31% | Orin Hirschman | 31 Dec 2025 |
As of 31 Mar 2026, 34 institutional investors reported holding 4,264,472 shares of Grace Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GRCE). This represents 25% of the company’s total 17,347,737 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
25%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Cerity Partners LLC | 4.9% | 849,055 | +101% | 0.01% | $3,931,125 |
| Eversept Partners, LP | 4.4% | 756,600 | 0.23% | $3,503,058 | |
| Nantahala Capital Management, LLC | 4.2% | 728,203 | -38% | 0.21% | $3,371,580 |
| BANK OF AMERICA CORP /DE/ | 2.9% | 494,723 | +0.01% | 0% | $2,290,568 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.3% | 401,656 | 0% | 0% | $1,859,667 |
| RENAISSANCE TECHNOLOGIES LLC | 1.4% | 243,910 | +88% | 0% | $1,129,303 |
| JANE STREET GROUP, LLC | 0.96% | 167,097 | 0% | $773,659 | |
| CITADEL ADVISORS LLC | 0.57% | 98,742 | +133% | 0% | $457,176 |
| MARSHALL WACE, LLP | 0.53% | 91,416 | 0% | $423,256 | |
| Connective Capital Management, LLC | 0.49% | 84,549 | 0.32% | $391,462 | |
| Quadrature Capital Ltd | 0.39% | 66,822 | 0% | $309,386 | |
| XTX Topco Ltd | 0.36% | 63,094 | +108% | 0.01% | $292,125 |
| Birchview Capital, LP | 0.29% | 50,000 | 0.13% | $231,500 | |
| Diametric Capital, LP | 0.23% | 39,796 | 0.05% | $184,255 | |
| Pale Fire Capital SE | 0.22% | 37,762 | 0.02% | $174,838 | |
| UBS Group AG | 0.15% | 26,301 | 0% | $121,774 | |
| KESTRA PRIVATE WEALTH SERVICES, LLC | 0.07% | 13,000 | 0% | $60,190 | |
| PRELUDE CAPITAL MANAGEMENT, LLC | 0.06% | 10,074 | 0% | $46,643 | |
| OPPENHEIMER & CO INC | 0.06% | 10,000 | 0% | $46,300 | |
| VANGUARD FIDUCIARY TRUST CO | 0.05% | 8,750 | 0% | 0% | $40,513 |
| BNP PARIBAS FINANCIAL MARKETS | 0.04% | 7,100 | 0% | 0% | $32,873 |
| GROUP ONE TRADING LLC | 0.03% | 5,000 | 0% | $23,150 | |
| MORGAN STANLEY | 0.03% | 4,548 | -82% | 0% | $21,057 |
| NATIONAL BANK OF CANADA /FI/ | 0.02% | 2,716 | 0% | 0% | $12,575 |
| WELLS FARGO & COMPANY/MN | 0.01% | 1,800 | 0% | $8,334 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
7
Latest
Q1 2026
Rows shown
1-7 of 7
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 4,264,472 | $19,744,993 | +$1,574,724 | $4.63 | 34 |
| 2025 Q4 | 4,327,617 | $14,995,992 | +$2,269,248 | $3.46 | 22 |
| 2025 Q3 | 3,706,227 | $11,033,102 | -$328,360 | $2.98 | 20 |
| 2025 Q2 | 3,816,908 | $11,344,205 | -$607,725 | $2.97 | 20 |
| 2025 Q1 | 4,024,092 | $9,168,718 | +$4,408,642 | $2.28 | 17 |
| 2024 Q4 | 2,087,877 | $7,835,456 | +$4,246,540 | $3.74 | 15 |
| 2024 Q3 | 959,571 | $2,878,713 | +$2,878,713 | $3.00 | 1 |